Amicus fail dents Pompe pipeline
Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.
Zimmer ditches slow-growing business to refocus
And the move will shake up the orthopaedic robotics scene.
Gene therapy trial fails to rectify Sarepta’s sorry record
Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.
Recycling pays off for Mereo
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Veklury boosts Gilead, yet disappoints too
With Gilead's big sellers forecast to drift, investors turn to its newer projects but find little comfort.
